Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), Akt-3 inhibitors(Serine/threonine-protein kinase AKT3 inhibitors), RSK inhibitors(Ribosomal protein S6 kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Diaccurate SAStartup |
Active Organization Diaccurate SAStartupMerck KGaA |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H19ClF3N5O |
InChIKeyHXAUJHZZPCBFPN-QGZVFWFLSA-N |
CAS Registry1379545-95-5 |
Start Date13 Dec 2013 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ER-positive/HER2-negative Breast Cancer | Phase 1 | FR | Diaccurate SAStartup | 22 Jul 2022 |
ER-positive/HER2-negative Breast Cancer | Phase 1 | - | 22 Jul 2022 | |
Stomach Cancer | Phase 1 | FR | Diaccurate SAStartup | 22 Jul 2022 |
Stomach Cancer | Phase 1 | - | 22 Jul 2022 | |
Glioblastoma Multiforme | Preclinical | FR | Diaccurate SAStartup | 17 Nov 2023 |
HER2 Positive Breast Cancer | Preclinical | FR | Diaccurate SAStartup | 17 Nov 2023 |
Solid tumor | Discovery | US | 13 Dec 2013 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 101 | (egbzjydpih) = no objective response was noted llrxuvigyo (vrfevpoqhx ) | - | 18 Aug 2021 | |||